ArticleFrontiers in immunology2026
The inhibitory effect of hepatic cancer energy metabolism on immune checkpoint therapy: perspectives from single-cell multi-omics analysis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate metabolic reprogramming-especially pyruvate metabolism-in hepatocellular carcinoma (HCC) before and after immune checkpoint inhibitor (ICI) therapy, construct a metabolism-related prognostic model, and evaluate the therapeutic potential of targeting LDHA. Methods: Integrated single-cell RNA-seq data (GEO, Mendeley) were analyzed using Seurat, AUCell, pySCENIC, CellChat, and Monocle. A prognostic model was developed from TCGA data by Cox and Lasso regression. Functional validation included Results: Post-ICI, HCC cells upregulated pyruvate metabolism genes (LDHA, LDHB, LDHD) but showed decreased glycolysis, lactate buildup, reduced acetylation, and suppressed TCA cycle with AMPK activation. Key transcription factors (MYC, SP5, HLF, SREBF1) were identified. CellChat revealed enhanced SPP1-CD44 and APOA1-ABCA1 signaling. Pseudotime analysis indicated terminal hepatocyte differentiation. The pyruvate metabolism-based signature predicted prognosis effectively. Combination therapy with (R)-GNE-140 and PD-1 blockade inhibited Huh7 proliferation, migration, and xenograft tumor growth without liver or renal toxicity. Conclusion: ICI therapy induces metabolic remodeling in HCC, marked by pyruvate metabolism dysregulation and lactate accumulation, contributing to resistance. Dual targeting of LDHA and PD-1 enhances antitumor efficacy, and the identified metabolic signature may serve as a prognostic biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.